{"id":52,"date":"2017-03-15T08:40:21","date_gmt":"2017-03-14T23:40:21","guid":{"rendered":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/pathophysiology\/?page_id=52"},"modified":"2022-02-02T11:13:03","modified_gmt":"2022-02-02T02:13:03","slug":"2011-2","status":"publish","type":"page","link":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/pathophysiology\/works\/2011-2\/","title":{"rendered":"2011"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n

\u25a0\u539f\u8457\u8ad6\u6587<\/p>\n

1. Matsuda S, Yamashita A, Sato Y, Kitajima S, Koike T, Sugita C, Moriguchi-Goto S, Hatakeyama K, Takahashi M, Koshimoto C, Matsuura Y, Iwakiri T, Chen YE, Fan J, Asada Y.Human C-reactive protein enhances thrombus formation after neointimal balloon injury in transgenic rabbits. J Thromb Haemost. 2011; 9: 201-8.<\/p>\n

2. Nakamura E, Tanaka N, Kuwabara M, Yamashita A, Matsuo Y, Kanai T, Onitsuka T, Asada Y, Hisa H, Yamamoto R. Relative contributions of 5-hydroxytryptamine (5-HT) receptor subtypes in 5-HT-induced vasoconstriction of the distended human saphenous vein as a coronary artery bypass graft. Biol Pharm Bull. 2011; 34: 82-6.<\/p>\n

3. Kuroiwa Y, Yamashita A, Miyati T, Furukoji E, Takahashi M, Azuma T, Sugimura H, Asanuma T, Tamura S, Kawai K, Asada Y. MR signal change in venous thrombus relates organizing process and thrombolytic response in rabbit. Magn Reson Imaging. 2011; 29: 975-8.<\/p>\n

4. Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H: C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17\/C-MYC. Am J Hematol.2011; 86: 75-8.<\/p>\n

5. Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y: Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators (Marutsuka K): Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011; 34: 280-5.<\/p>\n

6. Sato S, Sato Y, Hatakeyama K, Marutsuka K, Yamashita A, Takeshima H, Asada Y.: Quantitative analysis of vessels with smooth muscle layer in astrocytic tumors: correltation with histological grade and prognostic significance. Histol Histopathol. 2011; 26: 497-504.<\/p>\n

7. Sato S, Sato Y, Marutsuka K, Takeshima H, Asada Y: Characteristics of tumour vessels in cytological squash smears of astrocytic tumours. Cytopathology. 2011; 22: 313-7.<\/p>\n

8. Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, Haferlach C, Siebert R, Dyer MJ, Asou N, Aburatani H, Nakakuma H, Kitamura T, Sonoki T : E\u03bc\/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia. 2011; 25: 1849-56.<\/p>\n

9. Matsuo Y, Kuwabara M, Tanaka-Totoribe N, Kanai T, Nakamura E, Gamoh S, Suzuki A, Asada Y, Hisa H, Yamamoto R. The defective protein level of myosin light chain phosphatase (MLCP) in the isolated saphenous vein, as a vascular conduit in coronary artery bypass grafting (CABG), harvested from patients with diabetes mellitus (DM). Biochem Biophys Res Commun. 2011; 412: 323-7.<\/p>\n

10. Kario K, Yano Y, Matsuo T, Hoshide S, Asada Y, Shimada K. Morning blood pressure surge, morning platelet aggregation, and silent cerebral infarction in older Japanese hypertensive patients. J Hypertens. 2011; 29: 2433-9.<\/p>\n

11. Nishi K, Imamura T, Kitamura K, Ogawa T, Fujimoto S, Kakitsubata Y, Ishikawa T, Asada Y, Kodama T. Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease. Ren Fail. 2011; 33: 398-404.<\/p>\n

\u25a0\u8457\u66f8<\/p>\n

1. \u7560\u5c71\u91d1\u592a\u3001\u677e\u6d66\u7950\u4e4b\u4ecb\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u7cd6\u5c3f\u75c5\u6027\u5927\u8840\u7ba1\u5408\u4f75\u75c7\u2015\u51a0\u52d5\u8108\u3001\u4f50\u7530\u6b63\u9686\u3001\u4e0b\u6751\u4f0a\u4e00\u90ce\u3001\u91ce\u51fa\u5b5d\u4e00\u3001\u7dbf\u7530\u88d5\u5b5d\u3000\u7de8\uff1a\u8840\u7ba1\u7cd6\u5c3f\u75c52011\u3001pp31-7 (2011)\u3001\u30d5\u30b8\u30e1\u30c7\u30a3\u30ab\u30eb\u51fa\u7248\uff08\u5927\u962a\uff09<\/p>\n

2. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u6813\u5f62\u6210\u6a5f\u5e8f\u3001\u6297\u8840\u6813\u85ac\u306e\u6700\u524d\u7dda\u2015\u57fa\u790e\u3068\u81e8\u5e8a\u2015\u3001pp18-34 (2011)\u3001\u658e\u85e4\u82f1\u5f66\u3000\u7de8\u3001\u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb\u793e\uff08\u5927\u962a\uff09<\/p>\n

3. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u7d44\u7e54\u56e0\u5b50\u3068\u7d44\u7e54\u56e0\u5b50\u6d3b\u6027\u963b\u5bb3\u56e0\u5b50\u3001pp136-137 (2011)\u3001\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4e8b\u5178\u3001\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u5b66\u4f1a\u7de8\u96c6\u3001\u671d\u5009\u66f8\u5e97\uff08\u6771\u4eac\uff09<\/p>\n

4. \u53e4\u5c0f\u8def\u82f1\u4e8c\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1aEcto-ATPDase\u3001pp147-148 (2011)\u3001\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4e8b\u5178\u3001\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u5b66\u4f1a\u7de8\u96c6\u3001\u671d\u5009\u66f8\u5e97\uff08\u6771\u4eac\uff09<\/p>\n

\u25a0\u7dcf\u8aac<\/p>\n

1. Yamashita A, Asada Y. A rabbit model of thrombosis on atherosclerotic lesions. J Biomed Biotechnol. 2011; 2011: 424929.<\/p>\n

2. \u5c71\u4e0b\u3000\u7be4\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u6813\u306e\u5897\u5927\u3001\u6210\u9577\u306e\u75c5\u7406\u57fa\u76e4\u3001\u8840\u7ba1\u533b\u5b66 2011; 12: 13-9.<\/p>\n

3. \u5c71\u4e0b\u3000\u7be4\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u75c5\u7406\u50cf\u3068\u8840\u6d41\u304b\u3089\u898b\u305f\u52d5\u8108\u786c\u5316\u3068\u8840\u6813\u306e\u518d\u691c\u8a3c\u3001\u8840\u6813\u6b62\u8840\u5b66\u4f1a\u8a8c 2011; 22: 3-10.<\/p>\n

4. \u4e38\u585a\u6d69\u52a9\u3001\u5f8c\u85e4\u6df8\u9999\uff1aC&I Update DIC\u306e\u75c5\u7406\u3001Coagulation and Inflammation 2011; 5: 1-6.<\/p>\n

5. \u4f50\u85e4\u4fe1\u4e5f\u3001\u5fb3\u6e80\u8cb4\u5b50\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u6280\u8853\u8b1b\u5ea7\u3001\u8853\u4e2d\u8fc5\u901f\u75c5\u7406\u7d44\u7e54\u8a3a\u65ad\u306b\u304a\u3051\u308b\u30a8\u30e9\u30b9\u30c1\u30ab\u30fbHE\u67d3\u8272\u3001Medical Technology 2011; 39: 475-81.<\/p>\n

6. \u4e38\u585a\u6d69\u52a9\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1aDIC?\u8a3a\u65ad\u30fb\u6cbb\u7642\u306e\u6700\u524d\u7dda\u3001DIC\u306e\u75c5\u614b\u751f\u7406\u30fb\u6700\u8fd1\u306e\u30c8\u30d4\u30c3\u30af\u30b9\u3001DIC\u306e\u81e8\u5e8a\u75c5\u7406\u3001DIC\u75c7\u4f8b\u306e\u75c5\u7406\u89e3\u5256\u6240\u898b\u3001\u533b\u5b66\u306e\u3042\u3086\u307f 2011; 238: 23-9.<\/p>\n

7. \u9db4\u7530 \u654f\u535a\u3001\u7560\u5c71 \u91d1\u592a\u3001\u5317\u6751 \u548c\u96c4\uff1a\u7279\u96c6\uff1a\u708e\u75c7\u3068\u52d5\u8108\u786c\u5316\u3001II. \u52d5\u8108\u786c\u5316\u306e\u6210\u56e0\u30fb\u75c5\u614b\u751f\u7406\u2015\u708e\u75c7\u3068\u306e\u304b\u304b\u308f\u308a\u3092\u4e2d\u5fc3\u306b\u30fc\u3000\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u30fb\u8840\u7ba1\u69cb\u7bc9\u7d30\u80de\u7fa4\u3001\u65e5\u672c\u81e8\u5e8a 2011; 69: 45-9.<\/p>\n

8. \u7560\u5c71\u91d1\u592a\u3001\u9db4\u7530 \u654f\u535a\u3001\u4e2d\u5cf6\u3000\u8c4a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u80f8\u90e8\u30fb\u8179\u90e8\u5927\u52d5\u8108\u7624\u3001\u75c5\u7406\u3068\u81e8\u5e8a 2011; 29: 226-31.<\/p>\n

9. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u306e\u708e\u75c7\u2015\u30d2\u30c8\u306e\u75c5\u7406\u304b\u3089\u307f\u305f\u52d5\u8108\u786c\u5316\u306e\u9032\u5c55\u6a5f\u69cb\u306b\u3064\u3044\u3066\u30fc\u3001\u8840\u7ba1\u533b\u5b66 2011; 12: 41-9.<\/p>\n

10. \u4f50\u85e4\u52c7\u4e00\u90ce\uff1a\u81cd\u5e2f\u7570\u5e38\u3001\u80ce\u5150\u6b7b\u4ea1\u3068\u80ce\u76e4\u75c5\u7406\u3001\u7523\u79d1\u3068\u5a66\u4eba\u79d1 2011; 95: 727-32.<\/p>\n

11. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u306b\u304a\u3051\u308b\u5e73\u6ed1\u7b4b\u7d30\u80de\u306e\u610f\u7fa9\u3001\u7d30\u80de 2011; 43: 554-7.<\/p>\n

12. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u767a\u75c7\u306b\u304a\u3051\u308b\u8840\u6813\u306e\u5f62\u6210\u6a5f\u5e8f\u3001\u5bae\u5d0e\u533b\u4f1a\u8a8c 2011; 35: 68-74.<\/p>\n

13. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u30a2\u30c6\u30ed\u30fc\u30e0\u8840\u6813\u75c7\u306b\u304a\u3051\u308b\u8840\u6813\u5f62\u6210\u6a5f\u69cb\u3001\u8840\u6db2\u30d5\u30ed\u30f3\u30c6\u30a4\u30a2 2011; 21: 1115-8.<\/p>\n

14. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u51a0\u52d5\u8108\u306e\u8840\u6813\u5f62\u6210\u30fb\u9032\u5c55\u6a5f\u5e8f\u3001\u65e5\u672c\u81e8\u5e8a 2011; 69(\u5897\u520a\u53f77): 123\uff0a7.<\/p>\n

\u25a0\u75c7\u4f8b\u5831\u544a<\/p>\n

1. Kuroiwa Y, Yamashita A, Nishihira K, Shibata Y, Matsuura Y, Maeda M, Asada Y. Cardiac Rupture in Acute Myocardial Infarction: Post-mortem MR Imaging. Magn Reson Med Sci. 2011; 10: 255-8.<\/p>\n

2. Matsuda S, Sato Y, Marutsuka K, Sameshima H, Michikata K, Ikenoue T, Soma H, Asada Y. Hemangioma of the umbilical cord with pseudocyst. Fetal Pediatr Pathol. 2011; 30: 16-21.<\/p>\n

3. Sameshima N, Marutsuka K, Tsukino H, Kamoto T, Kono S, Asada Y. So-called \u201cadenosarcoma\u201d of the kidney: a novel adult renal tumor with a cystic appearance. Pathol Int. 2011; 61: 313-8.<\/p>\n

4. Amano M, Marutsuka K, Nakayama F, Todaka T, Sugimoto T, Setoyama M. Epstein-Barr virus-associated primary central nervous system B-cell lymphoma arising in a patient with adult T-cell leukemia\/lymphoma. J Dermatol. 2011; 38: 575-80.<\/p>\n

5. Yamasaki K, Sugimoto T, Futami M, Moriyama T, Uehara H, Taeshima H, Moriguchi S, Marutsuka K, Asada Y. Granulomatous amoebic encephalitis caused by Balamuthia Mandrillaris. Neurol Med Chir. 2011; 51: 667-70.<\/p>\n

6. \u5c71\u4e0b\u3000\u7be4\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u80a5\u5f8c\u8cb4\u53f2\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u5b50\u5bae\u9838\u90e8\u817a\u69d8\u57fa\u5e95\u7d30\u80de\u4e0a\u76ae\u816b\u3068\u5b50\u5bae\u985e\u5185\u819c\u817a\u764c\u304c\u4f75\u5b58\u3057\u305f\uff11\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406 2011; 28: 203-6.<\/p>\n

7. \u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u767d\u5c3e\u4e00\u5b9a\u3001\u82b1\u725f\u79ae\u767b\u7f8e\u96c4\u3001\u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u30e9\u30d6\u30c9\u30a4\u30c9\u5f62\u8cea\u3092\u4f34\u3046\u80ba\u5927\u7d30\u80de\u764c\u306e\uff11\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406 2011; 28: 130-3.<\/p>\n

8. \u91ce\u53e3\u88d5\u53f2\u3001\u82b1\u725f\u793c\u5bcc\u7f8e\u96c4\u3001\u672b\u5ddd\u667a\u5b50\u3001\u4f50\u85e4\u4fe1\u4e5f\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u5fc3\u56a2\u6db2\u306b\u767a\u751f\u3057\u305fHHV-8\u611f\u67d3\u9670\u6027primary effusion lymphoma\u306e\uff11\u4f8b\u3001\u65e5\u81e8\u7d30\u80de\u8a8c 2011; 50: 220-5.<\/p>\n

9. \u5927\u91ce\u62db\u4f38\u3001\u4f50\u85e4\u4fe1\u4e5f\u3001\u5fb3\u6e80\u8cb4\u5b50\u3001\u795e\u7530\u4fee\u53f8\u3001\u6cb3\u91ce\u6587\u5f70\u3001\u76db\u53e3\u6df8\u9999\u3001\u7530\u4e2d\u5f18\u4e4b\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u7a7f\u523a\u5438\u5f15\u7d30\u80de\u8a3a\u3067\u8a3a\u65ad\u3057\u5f97\u305f\u5341\u4e8c\u6307\u8178\u5185\u5206\u6ccc\u816b\u760d\u306e\uff11\u4f8b\u3001\u65e5\u81e8\u7d30\u80de\u4f1a\u4e5d\u5dde\u4f1a\u8a8c 2011; 42: 55-9.<\/p>\n

10. \u7b20\u65b0\u9038\u3001\u5c71\u4e0b\u771f\u6cbb\u3001\u5185\u4e4b\u5009\u4fca\u6717\u3001\u5bae\u7530\u53f2\u6717\u3001\u6c60\u30ce\u4e0a\u5b9f\u3001\u6fa4\u5927\u4ecb\u3001\u5c71\u7530\u76f4\u53f2\u3001\u5150\u7389\u7531\u7d00\u3001\u76db\u53e3\u6df8\u9999\u3001\u4e38\u585a\u6d69\u52a9\u3001\u4e2d\u91cc\u6d0b\u4e00\u3001\u6a2a\u4e0a\u8056\u8cb4\u3001\u4e0a\u539f\u4e45\u751f\u3001\u7af9\u5cf6\u79c0\u96c4\uff1a\u80ce\u5150\u671f\u306b\u8a3a\u65ad\u3055\u308c\u305f\u5de8\u5927\u5148\u5929\u6027\u9000\u5f62\u6210\u6027\u661f\u7d30\u80de\u816b\u306e\uff11\u4f8b\u3001\u8133\u5916\u901f\u5831 2011; 21: 1040-5. 11. \u76db\u53e3\u6df8\u9999\u3001\u6d45\u7530\u7950\u58eb\u90ce\u3001\u4e45\u51a8\u6728\u5eb8\u5b50\uff64\u4e0b\u7530\u548c\u54c9\u3001\u4e38\u585a\u6d69\u52a9\uff1a\uff28\uff29\uff36\u9670\u6027\u60a3\u8005\u306e\u6b6f\u8089\u306b\u767a\u751f\u3057\u305fPlasmablastic lymphoma\u306e1\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406 2011; 28: 284-7.<\/p>\n

12. \u5e16\u4f50\u5ba3\u662d\u3001\u9ed2\u5ca9\u4e9c\u7531\u5b50\u3001\u702c\u6238\u5c71\u5145\u3001\u6960\u539f\u548c\u6717\u3001\u76db\u53e3\u6df8\u9999\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u653e\u5c04\u7dda\u3068\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u4f75\u7528\u306b\u3066\u6cbb\u7642\u3057\u305f\u4e0b\u817f\u306eAngiosarcoma Associated with Lymphedema\u306e\uff11\u4f8b\u3001\u897f\u65e5\u672c\u76ae\u819a\u79d1 2011; 73: 593-7.<\/p>\n<\/div>\n<\/article>\n<\/div>\n<\/section>\n

\n